Drug

Vixarelimab

Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Subcutaneous (SC) Injection
Funder Type:
Industry

Drug Details

Vixarelimab is an investigational fully human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation, and fibrosis.

Study Purpose

The main purpose of the study is to evaluate the efficacy and safety of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Find a Clinical Trial